ÃÖ°æÈ
¼Ò
¼Ó
: ºÐ´çÂ÷º´¿ø
Àü¹®ºÐ¾ß : ¿ä½Ç±Ý/¹è´¢Àå¾Ö/°á¼®/Ç÷´¢/¹æ±¤¿°/°£Áú¼º¹æ±¤¿°/¼Ò¾Æºñ´¢
Á÷
ˤ
: ºÎ±³¼ö
¸Þ
ÀÏ
:
ºñ°ø°³
Àü
È
:
1577-4488
ÆÑ
½º
:
ÁÖ
¼Ò
:
°æ±âµµ ¼º³²½Ã ºÐ´ç±¸ ¾ßž·Î 59
ȨÆäÀÌÁö:
ÅǸ޴º
ÁÖ¿ä¹ßÇ¥³í¹®
¹øÈ£
±¸ºÐ
Á¦¸ñ
´Ù¿î·Îµå
39
ÇØ¿Ü
Mitochondrial Sirt3 supports cell proliferation by regulating glutamine-dependent oxidation in renal cell carcinoma
38
ÇØ¿Ü
Renoprotective Mechanism of Remote Ischemic Preconditioning Based on Transcriptomic Analysis in a Porcine Renal Ischemia Reperfusion Injury Model.
37
ÇØ¿Ü
Sorafenib treatment for recurrent stage T1 bilateral renal cell carcinoma in patients with Von Hippel- Lindau disease: A case report and literature review.
36
ÇØ¿Ü
The Youngest Korean Case of Urachal Carcinoma.
35
ÇØ¿Ü
Clinical Assessment of Lipid Profiles in Live Kidney Donors
34
ÇØ¿Ü
Preconditioning Strategies for Kidney Ischemia Reperfusion Injury: Implications of the "Time-Window" in Remote Ischemic Preconditioning
33
ÇØ¿Ü
Impact of Metabolic Syndrome on Postdonation Renal Function in Living Kidney Donors
32
±¹³»
Impact of adjuvant chemotherapy in patients with upper tract urothelial carcinoma and lymphovascular invasion after radical nephroureterectomy
31
±¹³»
Management of Pelvic Organ Prolapse
30
ÇØ¿Ü
Contralateral kidney volume change as a consequence of ipsilateral parenchymal atrophy promotes overall renal function recovery after partial nephrectomy.
1
2
3
4
5
Copyright ¨Ï chamc, All rights reserved.
ºü¸£°í Æí¸®ÇÑ ÀÎÅÍ³Ý Áø·á¿¹¾à
Àüȹ®ÀÇ
°³²Â÷º´¿ø 02.3468.3000
ºÐ´çÂ÷º´¿ø 031.780.5000
Â÷¿ò 02.3015.5300
±¸¹ÌÂ÷º´¿ø 054.450.9700
´ë±¸¿©¼ºÂ÷º´¿ø 02.222.4200
°³²°ÇÁø¼¾ÅÍ 02.2191.3900
ºÐ´çÁ¾ÇÕ°Ç°ÁõÁø¼¾ÅÍ 031.780.5940
½ºÆ÷·º½º °ÇÁø¼¾ÅÍ 02.3473.2111
±¸¹ÌÂ÷º´¿ø°ÇÁø¼¾ÅÍ 054.450.9800
ȨÆäÀÌÁö°ü¸®ÀÚ 031.780.1729